James Howard Tonsgard to Humans
This is a "connection" page, showing publications James Howard Tonsgard has written about Humans.
Connection Strength
0.145
-
Clinical manifestations and management of neurofibromatosis type 1. Semin Pediatr Neurol. 2006 Mar; 13(1):2-7.
Score: 0.009
-
Multicenter, prospective, phase II study of maintenance bevacizumab for children and adults with NF2-related schwannomatosis and progressive vestibular schwannoma. Neuro Oncol. 2023 08 03; 25(8):1498-1506.
Score: 0.008
-
Current Recommendations for Patient-Reported Outcome Measures Assessing Domains of Quality of Life in Neurofibromatosis Clinical Trials. Neurology. 2021 08 17; 97(7 Suppl 1):S50-S63.
Score: 0.007
-
NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas. J Clin Oncol. 2021 03 01; 39(7):797-806.
Score: 0.006
-
Dural Ectasia in Neurofibromatosis 1: Case Series, Management, and Review. Neurosurgery. 2020 05 01; 86(5):646-655.
Score: 0.006
-
Cognition, ADHD Symptoms, and Functional Impairment in Children and Adolescents With Neurofibromatosis Type 1. J Atten Disord. 2021 06; 25(8):1177-1186.
Score: 0.006
-
Reproducibility of cognitive endpoints in clinical trials: lessons from neurofibromatosis type 1. Ann Clin Transl Neurol. 2019 12; 6(12):2555-2565.
Score: 0.006
-
Multicenter, Prospective, Phase II and Biomarker Study of High-Dose Bevacizumab as Induction Therapy in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannoma. J Clin Oncol. 2019 12 10; 37(35):3446-3454.
Score: 0.006
-
CT imaging in adults with neurofibromatosis-1: frequent asymptomatic plexiform lesions. Neurology. 1998 Jun; 50(6):1755-60.
Score: 0.005
-
Do NF1 gene deletions result in a characteristic phenotype? Am J Med Genet. 1997 Nov 28; 73(1):80-6.
Score: 0.005
-
Randomized placebo-controlled study of lovastatin in children with neurofibromatosis type 1. Neurology. 2016 Dec 13; 87(24):2575-2584.
Score: 0.005
-
Patient-reported outcomes of pain and physical functioning in neurofibromatosis clinical trials. Neurology. 2016 Aug 16; 87(7 Suppl 1):S4-S12.
Score: 0.005
-
High Incidence of Noonan Syndrome Features Including Short Stature and Pulmonic Stenosis in Patients carrying NF1 Missense Mutations Affecting p.Arg1809: Genotype-Phenotype Correlation. Hum Mutat. 2015 Nov; 36(11):1052-63.
Score: 0.004
-
Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a neurofibromatosis Clinical Trials Consortium phase II study. Neuro Oncol. 2015 Apr; 17(4):596-603.
Score: 0.004
-
Patient-reported outcomes in neurofibromatosis and schwannomatosis clinical trials. Neurology. 2013 Nov 19; 81(21 Suppl 1):S6-14.
Score: 0.004
-
Cognitive and psychosocial phenotype of young children with neurofibromatosis-1. J Int Neuropsychol Soc. 2014 Jan; 20(1):88-98.
Score: 0.004
-
Impaired fatty acid oxidation in children on valproic acid and the effect of L-carnitine. Neurology. 1993 Nov; 43(11):2362-8.
Score: 0.004
-
The ophthalmologic presentation of NF-2 in childhood. J Pediatr Ophthalmol Strabismus. 1993 Sep-Oct; 30(5):327-30.
Score: 0.004
-
Cerebral malformations in Carpenter syndrome. Pediatr Neurol. 1993 May-Jun; 9(3):230-4.
Score: 0.004
-
Expression profiling of 519 kinase genes in matched malignant peripheral nerve sheath tumor/plexiform neurofibroma samples is discriminatory and identifies mitotic regulators BUB1B, PBK and NEK2 as overexpressed with transformation. Mod Pathol. 2013 Jul; 26(7):930-43.
Score: 0.004
-
In vitro microelectrode study of neuromuscular transmission in a case of botulism. Muscle Nerve. 1992 Mar; 15(3):273-6.
Score: 0.003
-
Defect in fatty acid oxidation: laboratory and pathologic findings in a patient. Pediatr Neurol. 1991 Mar-Apr; 7(2):125-30.
Score: 0.003
-
Neoplasms with schwannian differentiation express transcription factors known to regulate normal schwann cell development. Int J Surg Pathol. 2010 Dec; 18(6):449-57.
Score: 0.003
-
Consensus recommendations to accelerate clinical trials for neurofibromatosis type 2. Clin Cancer Res. 2009 Aug 15; 15(16):5032-5039.
Score: 0.003
-
Effect of Reye's syndrome serum on the ultrastructure of isolated liver mitochondria. Lab Invest. 1989 Apr; 60(4):568-73.
Score: 0.003
-
Binding of straight-chain saturated dicarboxylic acids to albumin. J Clin Invest. 1988 Nov; 82(5):1567-73.
Score: 0.003
-
Kluver-Bucy syndrome in children. Pediatr Neurol. 1987 May-Jun; 3(3):162-5.
Score: 0.002
-
Serum dicarboxylic acids in patients with Reye syndrome. J Pediatr. 1986 Sep; 109(3):440-5.
Score: 0.002
-
Effect of Reye's syndrome serum on isolated chinchilla liver mitochondria. J Clin Invest. 1985 Aug; 76(2):816-25.
Score: 0.002
-
Urinary dicarboxylic acids in Reye syndrome. J Pediatr. 1985 Jul; 107(1):79-84.
Score: 0.002
-
Decompressive hemicraniectomy in a 6-year-old male after unilateral hemispheric stroke. Case report and review. Pediatr Neurosurg. 2003 Apr; 38(4):181-5.
Score: 0.002
-
Lactic acidemia in Reye's syndrome. Pediatrics. 1982 Jan; 69(1):64-9.
Score: 0.002
-
Salicylates and Reye's syndrome. Pediatrics. 1981 Nov; 68(5):747-8.
Score: 0.002
-
Late-onset neurofibromatosis in a liver transplant recipient. Int J Dermatol. 2000 May; 39(5):376-9.
Score: 0.002
-
A child with neurofibromatosis-1 and a lumbar epidural arteriovenous malformation. J Child Neurol. 2000 Apr; 15(4):273-5.
Score: 0.002
-
Descriptive analysis of tibial pseudarthrosis in patients with neurofibromatosis 1. Am J Med Genet. 1999 Jun 11; 84(5):413-9.
Score: 0.001
-
A novel disease with deficiency of mitochondrial very-long-chain acyl-CoA dehydrogenase. Biochem Biophys Res Commun. 1993 Mar 31; 191(3):1369-72.
Score: 0.001